CJC-1295 with DAC (Drug Affinity Complex) is the long-acting version of the modified growth hormone-releasing hormone analog. The DAC component consists of a maleimidopropionyl group attached to a lysine residue that allows the peptide to covalently bind to serum albumin after injection. This albumin binding dramatically extends the half-life from minutes to approximately 8 days, allowing for once or twice weekly administration. The sustained elevation of GH and IGF-1 levels makes this version suitable for long-term research applications requiring consistent anabolic signaling. CJC-1295 with DAC maintains pulsatile GH release while providing sustained baseline elevation.
Key Data
Mechanism of Action
GHRH analog with DAC modification allowing albumin binding, creating depot effect for prolonged GH release.
Reported Benefits
All information is presented for Research Use Only (RUO). Not medical advice.